These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15554932)

  • 1. Institutional review board approval for clinical application of new medical devices rather than government agency.
    Nosé Y
    Artif Organs; 2004 Dec; 28(12):1057-8. PubMed ID: 15554932
    [No Abstract]   [Full Text] [Related]  

  • 2. IRBs and Humanitarian Device Exemptions (HDEs).
    Maloney DM
    Hum Res Rep; 2001 Sep; 16(9):4. PubMed ID: 11833567
    [No Abstract]   [Full Text] [Related]  

  • 3. Innovative tools, regulatory bodies, and the creative surgeon.
    Reilly JS
    Arch Otolaryngol Head Neck Surg; 2003 Jun; 129(6):678. PubMed ID: 12810478
    [No Abstract]   [Full Text] [Related]  

  • 4. Express preemption and premarket approval under the Medical Device Amendments.
    Scandaglia GJ; Tully TL
    Food Drug Law J; 2004; 59(2):245-64. PubMed ID: 15318395
    [No Abstract]   [Full Text] [Related]  

  • 5. A pivotal medical-device case.
    Greenspan H
    N Engl J Med; 2008 Apr; 358(16):1758. PubMed ID: 18420514
    [No Abstract]   [Full Text] [Related]  

  • 6. Case study: agency says institutional review board (IRB) did not fulfill duties so agency investigation expands.
    Maloney DM
    Hum Res Rep; 2006 Apr; 21(4):6-7. PubMed ID: 16832919
    [No Abstract]   [Full Text] [Related]  

  • 7. Institutional review board approval-more red tape or a step in the right direction?
    Rushton HG
    J Urol; 2008 Sep; 180(3):804-5. PubMed ID: 18635239
    [No Abstract]   [Full Text] [Related]  

  • 8. Devices and the food and drug administration.
    Phillips SJ; Phillips RS
    Artif Organs; 2005 May; 29(5):363-5. PubMed ID: 15854210
    [No Abstract]   [Full Text] [Related]  

  • 9. A pivotal medical-device case.
    Picca SM
    N Engl J Med; 2008 Apr; 358(16):1758. PubMed ID: 18426011
    [No Abstract]   [Full Text] [Related]  

  • 10. Continued concern: human subject protection, the institutional review board, and continuing review.
    Hoffman S
    Tenn Law Rev; 2001; 68(4):725-70. PubMed ID: 16189912
    [No Abstract]   [Full Text] [Related]  

  • 11. When informed consent is not required in studies.
    Maloney DM
    Hum Res Rep; 2006 Jun; 21(6):3. PubMed ID: 17111532
    [No Abstract]   [Full Text] [Related]  

  • 12. Roles and actions of IRBs as it relates to the process of drug and device development.
    Silverstein JH; Bienstock C
    Mt Sinai J Med; 2008; 75(1):59-62. PubMed ID: 18306252
    [No Abstract]   [Full Text] [Related]  

  • 13. Institutional review board reform.
    Mann H
    N Engl J Med; 2002 Oct; 347(16):1285-6. PubMed ID: 12397664
    [No Abstract]   [Full Text] [Related]  

  • 14. A pivotal medical-device case.
    Sonder G
    N Engl J Med; 2008 Apr; 358(16):1758. PubMed ID: 18426012
    [No Abstract]   [Full Text] [Related]  

  • 15. [Development and evaluation of new drugs and medical devices in Japan--standpoint of regulatory agency].
    Maruyama H; Kondo T
    Brain Nerve; 2010 Mar; 62(3):263-8. PubMed ID: 20297731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PMA primacy: synthesizing the 35 U.S.C. Section 156 patent term extension, 35 U.S.C. Section 271(e)(1) patent infringement exemption as currently applied to medical devices, and medical device preemption jurisprudence to yield a cohesive solution regarding scope of coverage.
    Flaherty JM
    Food Drug Law J; 2001; 56(3):339-49. PubMed ID: 11944643
    [No Abstract]   [Full Text] [Related]  

  • 17. The FDA's role in medical device clinical studies of human subjects.
    Saviola J
    J Neural Eng; 2005 Mar; 2(1):S1-4. PubMed ID: 15876645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical research oversight from the corporate governance perspective: comparing institutional review boards and corporate boards.
    Saver RS
    William Mary Law Rev; 2004 Nov; 46(2):619-730. PubMed ID: 17167924
    [No Abstract]   [Full Text] [Related]  

  • 19. Bringing new nebulizer technologies to market: regulatory issues.
    Meyer RJ
    Respir Care; 2002 Nov; 47(11):1334-6. PubMed ID: 12425748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protecting vulnerable research subjects: practical realities of institutional review board review and approval.
    Wichman A
    J Health Care Law Policy; 1998; 1(1):88-104. PubMed ID: 15573431
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.